S&P 500   5,051.38 (-0.21%)
DOW   37,798.77 (+0.17%)
QQQ   432.03 (+0.23%)
AAPL   169.67 (-1.75%)
MSFT   415.79 (+0.52%)
META   501.35 (+0.22%)
GOOGL   154.75 (-0.07%)
AMZN   183.81 (+0.10%)
TSLA   157.14 (-2.69%)
NVDA   877.64 (+2.05%)
AMD   163.53 (+2.00%)
NIO   3.84 (-1.29%)
BABA   69.89 (-1.03%)
T   16.08 (-0.99%)
F   12.17 (-0.49%)
MU   122.06 (+0.57%)
GE   156.46 (+1.80%)
CGC   6.70 (-4.01%)
DIS   113.99 (+0.92%)
AMC   2.78 (+12.55%)
PFE   25.74 (-0.66%)
PYPL   63.71 (+0.31%)
XOM   118.81 (-0.73%)
S&P 500   5,051.38 (-0.21%)
DOW   37,798.77 (+0.17%)
QQQ   432.03 (+0.23%)
AAPL   169.67 (-1.75%)
MSFT   415.79 (+0.52%)
META   501.35 (+0.22%)
GOOGL   154.75 (-0.07%)
AMZN   183.81 (+0.10%)
TSLA   157.14 (-2.69%)
NVDA   877.64 (+2.05%)
AMD   163.53 (+2.00%)
NIO   3.84 (-1.29%)
BABA   69.89 (-1.03%)
T   16.08 (-0.99%)
F   12.17 (-0.49%)
MU   122.06 (+0.57%)
GE   156.46 (+1.80%)
CGC   6.70 (-4.01%)
DIS   113.99 (+0.92%)
AMC   2.78 (+12.55%)
PFE   25.74 (-0.66%)
PYPL   63.71 (+0.31%)
XOM   118.81 (-0.73%)
S&P 500   5,051.38 (-0.21%)
DOW   37,798.77 (+0.17%)
QQQ   432.03 (+0.23%)
AAPL   169.67 (-1.75%)
MSFT   415.79 (+0.52%)
META   501.35 (+0.22%)
GOOGL   154.75 (-0.07%)
AMZN   183.81 (+0.10%)
TSLA   157.14 (-2.69%)
NVDA   877.64 (+2.05%)
AMD   163.53 (+2.00%)
NIO   3.84 (-1.29%)
BABA   69.89 (-1.03%)
T   16.08 (-0.99%)
F   12.17 (-0.49%)
MU   122.06 (+0.57%)
GE   156.46 (+1.80%)
CGC   6.70 (-4.01%)
DIS   113.99 (+0.92%)
AMC   2.78 (+12.55%)
PFE   25.74 (-0.66%)
PYPL   63.71 (+0.31%)
XOM   118.81 (-0.73%)
S&P 500   5,051.38 (-0.21%)
DOW   37,798.77 (+0.17%)
QQQ   432.03 (+0.23%)
AAPL   169.67 (-1.75%)
MSFT   415.79 (+0.52%)
META   501.35 (+0.22%)
GOOGL   154.75 (-0.07%)
AMZN   183.81 (+0.10%)
TSLA   157.14 (-2.69%)
NVDA   877.64 (+2.05%)
AMD   163.53 (+2.00%)
NIO   3.84 (-1.29%)
BABA   69.89 (-1.03%)
T   16.08 (-0.99%)
F   12.17 (-0.49%)
MU   122.06 (+0.57%)
GE   156.46 (+1.80%)
CGC   6.70 (-4.01%)
DIS   113.99 (+0.92%)
AMC   2.78 (+12.55%)
PFE   25.74 (-0.66%)
PYPL   63.71 (+0.31%)
XOM   118.81 (-0.73%)

Werewolf Therapeutics (HOWL) Earnings Date, Estimates & Call Transcripts

$5.62
+0.13 (+2.37%)
(As of 03:46 PM ET)

Earnings Summary

Upcoming
Earnings Date
May. 9Estimated
Actual EPS
(Mar. 7)
-$0.33 Beat By $0.10
Consensus EPS
(Mar. 7)
-$0.43
Skip Charts & View Estimated and Actual Earnings Data

HOWL Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HOWL Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Werewolf Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.31)($0.31)($0.31)
Q2 20241($0.33)($0.33)($0.33)
Q3 20241($0.30)($0.30)($0.30)
Q4 20241($0.31)($0.31)($0.31)
FY 20244($1.25)($1.25)($1.25)

HOWL Earnings Date and Information

Werewolf Therapeutics last posted its earnings results on March 7th, 2024. The reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.10. The business earned $1.50 million during the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics has generated ($1.04) earnings per share over the last year (($1.04) diluted earnings per share). Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.38) to ($1.60) per share. Werewolf Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.

Werewolf Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/9/2024
Estimated)
------- 
3/7/2024Q4 2023($0.43)($0.33)+$0.10($0.33)$2.75 million$1.50 million
11/14/2023Q3 2023($0.27)($0.23)+$0.04($0.23)$15.60 million$5.90 million
8/10/2023Q2 2023($0.41)($0.14)+$0.27($0.14)$3.05 million$8.08 million
5/11/2023Q1 2023($0.49)($0.34)+$0.15($0.34)$3.05 million$4.46 million
3/23/2023Q4 2022($0.59)($0.39)+$0.20($0.39)$3.15 million$7.28 million
11/10/2022Q3 2022($0.60)($0.40)+$0.20($0.40)$6.10 million$4.97 million
8/11/2022Q2 2022($0.30)($0.53)($0.23)($0.53)$15.00 million$4.15 million
5/10/2022Q1 2022($0.60)($0.56)+$0.04($0.56)--
3/24/2022Q4 2021($0.56)($0.66)($0.10)($0.66)--
11/10/2021Q3 2021($0.45)($0.51)($0.06)($0.51)--
8/12/2021Q2 2021($0.37)($3.82)($3.45)($3.82)--
6/10/2021Q1 2021($0.43)($83.36)($82.93)($83.36)--

Werewolf Therapeutics Earnings - Frequently Asked Questions

When is Werewolf Therapeutics's earnings date?

Werewolf Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on HOWL's earnings history.

Did Werewolf Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Werewolf Therapeutics (NASDAQ:HOWL) reported ($0.33) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.43) by $0.10. Learn more on analysts' earnings estimate vs. HOWL's actual earnings.

How much revenue does Werewolf Therapeutics generate each year?

Werewolf Therapeutics (NASDAQ:HOWL) has a recorded annual revenue of $19.94 million.

How much profit does Werewolf Therapeutics generate each year?

Werewolf Therapeutics (NASDAQ:HOWL) has a recorded net income of -$37.37 million. HOWL has generated -$1.04 earnings per share over the last four quarters.

What is Werewolf Therapeutics's EPS forecast for next year?

Werewolf Therapeutics's earnings are expected to decrease from ($1.38) per share to ($1.60) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:HOWL) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners